This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-22. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Lex Politica also represented the non-profit arm in the US of Victor Orban's Danube Institute. Gober was also involved in the 2025 redistricting process. Republican mapmaker Kincaid testified that the Republican National Committee retained Gober to represent the Texas Republican congressional delegation and that Gober conveyed the delegation's requests to him during the map-drawing process. Gober's congressional campaign subsequently listed his redistricting work among his accomplishments, stating that he had helped deliver a redistricting plan that strengthened the Republican majority and describing the result as having "Secured Five New Republican Seats." Gober won the Republican nomination for Texas’ redrawn 10th Congressional District with 51.2 percent of the vote, narrowly avoiding a runoff. Gober is running on a platform of strict border security, “America First” economic policies, and the “weaponization of government” against conservative causes. The incumbent is Republican Michael McCaul, who was re-elected in 2024 with 63.6% of the vote. McCaul is not seeking reelection in the redrawn district, which gave 60.5% of the vote to Donald Trump and 58.4% to Ted Cruz in 2024.
Hemoglobin is the principal determinant of the color of blood (hemochrome). Each molecule has four heme groups, and their interaction with various molecules alters the exact color. Arterial blood and capillary blood are bright red, as oxygen imparts a strong red color to the heme group. Deoxygenated blood is a darker shade of red; this is present in veins, and can be seen during blood donation and when venous blood samples are taken. This is because the spectrum of light absorbed by hemoglobin differs between the oxygenated and deoxygenated states. Blood in carbon monoxide poisoning is bright red, because carbon monoxide causes the formation of carboxyhemoglobin. In cyanide poisoning, the body cannot use oxygen, so the venous blood remains oxygenated, increasing the redness. There are some conditions affecting the heme groups present in hemoglobin that can make the skin appear blue – a symptom called cyanosis. If the heme is oxidized, methemoglobin, which is more brownish and cannot transport oxygen, is formed. In the rare condition sulfhemoglobinemia, arterial hemoglobin is partially oxygenated, and appears dark red with a bluish hue. Veins close to the surface of the skin appear blue for a variety of reasons. However, the factors that contribute to this alteration of color perception are related to the light-scattering properties of the skin and the processing of visual input by the visual cortex, rather than the actual color of the venous blood. Skinks in the genus Prasinohaema have green blood due to a buildup of the waste product biliverdin.
In 2024, circana tracked approximately 11,000 unauthorized flavored disposable vape products in U.S. mainstream retail outlets, according to data reviewed by Reuters. In 2024, illegal sales of flavored disposable vapes reached about $2.4 billion and accounted for roughly 35% of all e-cigarette sales in mainstream retail outlets. According to data reviewed by Reuters, Circana estimated the total tracked vape market at $6.8 billion, excluding online and specialty store sales. A 2025 lawsuit by New York's attorney general cited testimony that one distributor sold more than $132 million worth of Elf Bar e-cigarettes in the prior year. Altria Group, one of the largest tobacco companies in the United States and the owner of Philip Morris USA, has significant investments in the domestic e-cigarette market. In January 2025, Altria said it was reassessing its 2028 "smoke-free" volume and revenue goals, citing competition from disposable vapes, and estimated that illicit disposable products represent 60% or more of the U.S. e-cigarette category despite lacking required authorizations. US authorities reported intensified enforcement actions against unauthorized e-cigarettes in 2025, including seizures of 4.7 million units valued at $86.5 million in a Chicago-based operation; US agencies also reported blocking more than 6 million unauthorized e-cigarettes worth over $120 million that year.
=== Advancements in Smart Polymers and Hydrogels === In recent years, advances in smart polymers and hydrogels have brought major improvements to how drugs are delivered in controlled-released systems. These materials are unique in that they can respond to changes inside the body, like shifts in pH, temperature, and glucose levels, making it possible to fine-tune when and how much of a drug is released. For example, some hydrogels are designed to expand or contract based on these internal signals, which helps regulate the speed of drug release. This kind of precision helps improves therapeutic treatment and reduces side effects. These responsive materials are useful for managing chronic condition like diabetes, where glucose-responsive hydrogels can adjust insulin release based on blood sugar levels.
== Early life and education == Caldwell Dyson was born in Arcadia, California. She is the younger of two girls. In the early 1980s, she and her family moved to Beaumont, California, where her father worked as an electrician and where she attended junior high school and high school. Her recreational interests include running, weight training, hiking, softball, basketball, and auto repair and maintenance. She attended California State University, Fullerton, where she competed on the CSUF Titans' track and field team as a sprinter and long jumper. As an undergraduate researcher at California State University, Fullerton, she designed, constructed and implemented electronics and hardware associated with a laser-ionization, time-of-flight mass spectrometer for studying atmospherically relevant gas-phase chemistry. She also worked as a lab assistant in the university's research and instructional safety office, where she performed environmental monitoring of laboratories using hazardous chemicals and radioactive materials and calibrated survey instruments and helped process chemical and radioactive waste. During college and after it, she also worked as an electrician and inside wireman for her father's electrical contracting company, where she performed commercial and light industrial construction. At the University of California, Davis, Caldwell Dyson taught general chemistry laboratory and began her graduate research.
Sources: en.wikipedia.org
Tetra Brik is a brand name for a carton package produced by the Swedish packaging company Tetra Pak. Its shape is cubic or cuboid, and it is available with or without various different caps. The Tetra Brik is the best-known and most sold package in the Tetra Pak packaging family, to the extent that Tetra Brik is sometimes mistaken for the brand name. The Tetra Brik comes in either chilled (Tetra Brik) or ambient (Tetra Brik Aseptic) package types.
== Precursors == Before the outbreak of World War II, Army commanders had recognized the inadequacy of heavy canned wet rations when employed for infantry marching on long patrols, especially in extreme environments such as mountain or jungle terrain. To this end, the Jungle ration was developed and briefly issued during early World War II. The Jungle ration was a dry, lightweight multi-component daily meal that could be stored in light waterproof bags, easily carried by a foot soldier, and which would not spoil when exposed to heat and humidity for an extended period of time. Importantly, the Jungle ration was specifically designed to provide an increased amount of dietary energy despite its lighter weight, ideal for a soldier operating in difficult jungle terrain on foot while carrying all of his equipment on his back. By all accounts the Jungle ration was successful; however, cost concerns led to its replacement, first by substitution of increasingly heavier and less expensive canned components, followed by complete discontinuance in 1943. After the war, U.S. Army logisticians again re-standardized field rations, eliminating all lightweight rations in favor of heavy canned wet rations such as the C-ration and the MCI. The overuse of heavy canned wet rations reached a ludicrous extreme during the early years of U.S. involvement in the Vietnam War, when American soldiers on extended infantry patrol were forced to stack their canned rations in socks to minimize weight and noise.
Mizell led the league in strikeouts with 257, finished second in ERA to Tom Gorman (1.97 to 1.94), and tied for seventh in the league with 16 wins. With a record of 99–61, Houston won the pennant by 13.5 games over the San Antonio Missions.
start codon The first codon translated by a ribosome from a mature messenger RNA transcript, used as a signal to initiate peptide synthesis. In the standard genetic code, the start codon always codes for the same amino acid, methionine, in eukaryotes and for a modified methionine in prokaryotes. The most common start codon is the triplet AUG. Contrast stop codon.
Covalent modification: Functionalization with carboxyl groups can reduce cellular and pulmonary toxicity by suppressing NLRP3 inflammasome activation and downregulating pro-inflammatory cytokines (e.g., IL-1β, TGF-β1, PDGF-AA). PEGylation, the covalent attachment of polyethylene glycol (PEG), reduces cellular uptake, protein adsorption, oxidative stress, and immune activation, reducing immune recognition and systemic inflammation.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.